BioMarin Pharmaceutical Inc. (BMRN) Stock: Price, Forecast & Analyst Target
BioMarin Pharmaceutical Inc. (BMRN) — MoonshotScore 58/100 (Fair band), calculated Nov 18, 2026. Price $61.43 (+4.99%), as of the Nov 18, 2026 trading session; market cap $11.9B. Expected results Feb 22, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 16.17× (cash as of Sep 30, 2026) · expected results Feb 22, 2027
BioMarin Pharmaceutical Inc. · BMRN · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: BioMarin sells treatments for severe rare genetic and metabolic disorders, with an established commercial portfolio rather than a business resting mainly on clinical milestones. The case depends on whether newer portfolio additions and patient growth can lift revenue while earnings, operating expenses and liquidity settle into a more durable pattern.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · BioMarin Pharmaceutical (BMRN)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet, weak growth and a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $776M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 5 of the last 8 reports
- Altman Z 1.91 · Piotroski F 2
Holding back: balance-sheet strain, soft growth
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 61 | Fair | |
| 61 | Fair | |
| 61 | Fair | |
| 61 | Fair | |
| 58 | Fair | |
| 58 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $61.43 | |
| Change on the day | +4.99% | |
| 52-week range | $49.26–$70.98 | |
| Market capitalisation | $11.9B | — |
| Price / earnings (trailing) | 153.97 | |
| Shares traded on the day | 3.07M | |
| Beta (volatility vs the S&P 500) | 0.23 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
More than 75% of revenue in the third quarter was generated outside of the U.S., and we expect this segment to be a leading area of expansion in achondroplasia.
Cristin Hubbard · Statement from
And our updated guidance is based on timing of revenue between Q4 and next year.
Brian R. Mueller · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for BioMarin Pharmaceutical (BMRN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioMarin Pharmaceutical (BMRN), and what does it report?
Short answer · as of
BioMarin earns nearly all of its revenue from medicines such as Vimizim, Naglazyme, Palynziq, Brineura and Voxzogo; royalties and other revenue are peripheral.
Research dated 2026-09-13.
Demand reflects diagnosed and treated patients, new therapy starts, dose progression and purchasing schedules across specialty pharmacies, hospitals, government health bodies, distributors and wholesalers.
That commercial base makes BioMarin different from a clinical-stage biotechnology company whose value depends chiefly on trial outcomes. Research remains substantial, but the reported income statement already measures a global rare-disease franchise with meaningful product sales and positive annual earnings.
What do the latest results show for BioMarin Pharmaceutical (BMRN)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $776M.
Research dated 2026-09-13.
The latest period delivered the strongest revenue in the reported quarterly series, positive operating and net income, and revenue and earnings above market expectations. Profit did not rise with sales, however: operating income and net income declined from the preceding period as research and administrative spending increased.
Management had previously expected purchasing schedules and fuller contributions from Galafold, Pombility and Opfolda to make the later part of the year stronger than the earlier part. That explanation identifies the commercial mechanism, but the expense pattern shows why revenue growth alone does not establish durable earnings growth.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.02B Sep 30, 2026
- Latest quarter · R&D
- $180.53M Sep 30, 2026
- Latest quarter · SG&A
- $333.64M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$82.08M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $1.02B | $180.53M | $333.64M | −$82.08M |
| Jun 30, 2026 | $989.71M | $206.95M | $395.54M | $110.93M |
| Mar 31, 2026 | $766.21M | $178.80M | $258.30M | $129.63M |
| Dec 31, 2025 | $874.57M | $192.41M | $802.12M | $79.39M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.02B Nov 2, 2026
- Latest report · revenue estimate
- $1.02B Nov 2, 2026
- Latest report · revenue vs estimate
- In line Nov 2, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 2, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 2, 2026 | $1.02B | $1.02B | $0.2300 | −$0.0493 |
| Aug 6, 2026 | $989.71M | $932.03M | $1.2000 | $0.9470 |
| May 4, 2026 | $766.00M | $752.53M | $0.7600 | $0.7800 |
| Feb 23, 2026 | $874.57M | $833.73M | −$0.2400 | $0.1694 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $776M | -$31M | -$0.16 (diluted) |
| Q4 FY2025 | $875M | -$47M | -$0.22 (diluted) |
| Q1 FY2026 | $766M | $106M | $0.54 (diluted) |
| Q2 FY2026 | $990M | $45M | $0.23 (diluted) |
What are the financial strengths and risks for BioMarin Pharmaceutical (BMRN)?
Short answer · as of
Cash and short-term investments were $736.01M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $188.21M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operations have generated cash throughout the reported quarterly window, while capital spending has remained modest relative to operating inflows. High gross profitability also gives BioMarin room to fund research and commercialization, although recent swings in operating and net margins show that this room can be consumed quickly.
Debt substantially exceeds cash and investments, and the latest cash balance fell sharply from the preceding period. Near-term liquidity ratios remain supportive, but cash alone would cover only a limited portion of total debt; the broader quality and distress screens therefore sit alongside genuine cash generation rather than replacing scrutiny of leverage.
The business-specific financial risk is that patient starts, titration or order timing disappoint while research and commercial costs remain elevated. Because revenue is overwhelmingly product based, disruption across the marketed portfolio would reach cash generation more directly than weakness in the small royalty stream.
Data-derived red flags
- Negative return on equity (-0.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 153.97 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $188.21M Sep 30, 2026
- Previous quarter · operating cash flow
- $168.11M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $188.21M | −$28.29M |
| Jun 30, 2026 | $168.11M | −$28.82M |
| Mar 31, 2026 | $220.65M | −$20.92M |
| Dec 31, 2025 | $99.64M | −$40.72M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at BioMarin Pharmaceutical (BMRN)?
Short answer · as of
The next earnings report is expected on Feb 22, 2027.
Research dated 2026-09-13.
Watch whether Galafold, Pombility and Opfolda provide the fuller contribution management anticipated, whether enzyme therapies sustain growth, and whether Palynziq gains from new patient starts and progression toward maintenance dosing. These observations test management's stated revenue mechanism rather than merely comparing the result with consensus.
The accompanying financial checks are whether operating profit keeps pace with revenue, operating cash flow remains positive and the cash balance stabilizes after its recent drop. Longer-range market estimates assume continued expansion in revenue and earnings, so recurring expense volatility or weak cash conversion would make that path harder to support.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
So what we will do as we near the launch and we gear up for it early in next year we will be sharing more about specifically what our expectations are around that and how we feel like we will be able to deliver on it and report out on it as we move forward.
Cristin Hubbard ·
It can take many months for a patient to titrate to a maintenance dose, so we expect the adolescent revenue contribution to build into 2027 and beyond.
Cristin Hubbard ·
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Oct 28, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does BioMarin Pharmaceutical compare with its peers?
Short answer
BioMarin Pharmaceutical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
BioMarin sits between a development-stage biotechnology company and a broad pharmaceutical manufacturer. It has multiple marketed rare-disease therapies, specialized distribution channels and substantial product revenue, yet its portfolio remains concentrated in small patient populations where diagnosis, treatment initiation, titration and purchasing schedules can materially affect sales timing.
Compared with pipeline-led peers, existing products provide revenue, gross profit and operating cash flow that can finance development work. Compared with diversified drugmakers, BioMarin retains greater exposure to individual rare-disease franchises and to the research and commercialization demands surrounding them.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $95.05 Nov 18, 2026 | $7.47B | 98 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $149.40 Nov 18, 2026 | $20.0B | 72 5-pillar Nov 18, 2026 | |
| BioMarin Pharmaceutical (BMRN) — this page | $61.43 | $11.9B | 58 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $59.00 – $122.00
- Consensus target
- $90.33
- Median target
- $90.00
Consensus record · Captured .
Measured against a quoted price of $61.43 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 12
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 1
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 96.1% Period end Sep 30, 2026
- Reporting holders
- 585 Period end Sep 30, 2026
- Previous quarter · holders
- 588 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 20,735,548 |
| Primecap Management Co/Ca/ | 14,988,996 |
| Dodge & Cox | 14,625,740 |
| Vanguard Capital Management LLC | 8,723,746 |
| Vanguard Portfolio Management LLC | 8,371,887 |
Tracked investors
Which of the 16 named investors we follow held BMRN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 1.32% | $430.39M | Trimmed −5.8% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0% | $0 | Sold out (was $15.73M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BioMarin Pharmaceutical (BMRN)?
What Investors Ask About BioMarin Pharmaceutical (BMRN) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Galafold, Pombility and Opfolda change BioMarin's commercial profile?
They broaden the enzyme-therapy portfolio beyond BioMarin's historical products. Management expected fuller contributions from these medicines to support stronger later-period revenue, making their commercial uptake important to the growth narrative.
Why can Palynziq sales move differently from patient starts?
Purchasing and stocking can shift revenue between reporting periods, while newly treated patients must progress toward maintenance dosing. Patient growth may therefore precede its full effect on reported sales.
What makes Voxzogo different from BioMarin's enzyme therapies?
Voxzogo is a daily injectable therapy for achondroplasia, whereas products such as Vimizim and Naglazyme replace enzymes for specific metabolic disorders. They share specialized rare-disease channels but address different conditions through different treatment mechanisms.
Does BioMarin rely mainly on its gene-therapy pipeline?
Marketed medicines already produce nearly all company revenue, so the business is not chiefly dependent on pipeline assets for current sales. Gene-therapy programs add development potential alongside an established commercial portfolio.
What is the BMRN stock price today?
The last price recorded for BioMarin Pharmaceutical Inc. (BMRN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BMRN price target?
The analyst consensus price target for BioMarin Pharmaceutical Inc. (BMRN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold BMRN
Funds in our ETF coverage that list BMRN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Global X - Genomics & Biotechnology ETF (GNOM) | 4.31% | |
| Alger Russell Innovation ETF (INVN) | 2.52% |